Another Heart Drug Fails, Shocking Cardiologists
Duke cardiologists including Neha Pagidipati, MD, are studying a twice-yearly injection for hypertension to improve patient adherence. The treatment aims to replace daily medications, which many patients find difficult to maintain, resulting in poorly controlled blood pressure. This research enters a period of volatility for cardiovascular treatments, where other trials have faced setbacks or unexpected enrollment challenges. While the Duke study focuses on chronic hypertension management, other recent cardiovascular news includes Cardiol Therapeutics expanding its Phase III MAVERIC trial for CardiolRx due to fewer disease recurrences than expected.
Listen to Live Briefing
Real-time synthesized voice briefing · Live Feeds Desk
- ✓ Neha Pagidipati, MD, and Duke cardiologists are studying a twice-yearly treatment for hypertension.
- ✓ Most people with hypertension do not have their blood pressure under control.
What changed
Duke University researchers are now testing a twice-yearly shot to treat hypertension.
Live updates
-
Duke Cardiologists Study Twice-Yearly Blood Pressure Injection
Duke cardiologists including Neha Pagidipati, MD, are studying a twice-yearly injection for hypertension to improve patient adherence. The treatment aims to replace daily medications, which many patients find difficult to maintain, resulting in poorly controlled blood pressure. This research enters a period of volatility for cardiovascular treatments, where other trials have faced setbacks or unexpected enrollment challenges. While the Duke study focuses on chronic hypertension management, other recent cardiovascular news includes Cardiol Therapeutics expanding its Phase III MAVERIC trial for CardiolRx due to fewer disease recurrences than expected.
Why it matters
Hypertension often remains uncontrolled because patients struggle with daily medication schedules. A long-acting injectable could remove this barrier to treatment adherence. This development follows recent failures in other drug trials, such as Roche's astegolimab for COPD.
What is confirmed
- Neha Pagidipati, MD, and Duke cardiologists are studying a twice-yearly treatment for hypertension.
- Most people with hypertension do not have their blood pressure under control.
What to watch next
- Clinical trial results for the Duke twice-yearly hypertension shot
- Updates on Cardiol Therapeutics Phase III MAVERIC trial expansion
confidence 100%Sources used for this update (3)
- jen.jiji.com — Autoimmune liver diseases, new strategy with nanocarriers in Italian study
- jen.jiji.com — Italy in the grip of bad weather, disturbance arriving with rain and downpours: Betti's (Cnr) forecasts
- medschool.duke.edu — Twice-yearly shot could transform blood pressure treatment
-
Cardiol Therapeutics Expands Trial After Unexpectedly Low Recurrence Rates
Cardiol Therapeutics is expanding its Phase III MAVERIC trial for CardiolRx, an oral treatment for recurrent pericarditis. President and CEO David Elsley stated the trial hit its enrollment target early, but fewer disease recurrences than expected have prompted the expansion. This development follows a pattern of volatility in cardiovascular drug trials, while other medical sectors face setbacks, such as Roche's COPD candidate astegolimab failing a phase 3 test. Separately, the FDA is investigating two deaths linked to black-market versions of the experimental weight-loss drug retatrutide.
Why it matters
Cardiovascular drug development remains unpredictable, with previous failures from Novartis and Novo Nordisk showing that hitting biological targets does not always prevent major health events. The current CardiolRx trial shift highlights how actual patient outcomes can deviate from predicted disease frequency. This occurs amid broader concerns over unapproved experimental drug knockoffs.
What is confirmed
- The FDA is investigating two deaths tied to black-market knockoffs of the experimental weight-loss drug retatrutide.
- Roche's COPD candidate astegolimab failed a phase 3 test.
- Cardiol Therapeutics reached its original enrollment target for the MAVERIC trial ahead of schedule.
Still unconfirmed
- The timing of beta-blocker treatment for cardiac arrest in thyroid storm remains an unresolved question according to a review of 78 cases.
- Cardiol Therapeutics plans to expand the MAVERIC trial because of fewer disease recurrences than anticipated.
What to watch next
- Results of the expanded MAVERIC trial for CardiolRx
- FDA findings regarding the retatrutide knockoff deaths
confidence 90%Sources used for this update (5)
- Bioengineer.org — When the Thyroid Stops the Heart: Landmark Review Maps Cardiac Arrest in Thyroid Storm
- thedeepdive.ca — Fewer Relapses, So Why Expand This Heart Drug Trial? | David ...
- www.medscape.com — Oct 16 2026 This Week in Cardiology - Medscape
- nypost.com — Two deaths linked to bootleg versions of unapproved weight ...
- pharmaphorum.com — Roche's COPD candidate fails a phase 3 readout | pharmaphorum
-
Cardiovascular Drug Failures Stir Scrutiny
Recent cardiovascular drug failures by pharmaceutical companies Novartis and Novo Nordisk highlight ongoing difficulties in medical treatment development, as these therapies failed to reduce major health events despite hitting biological targets. Meanwhile, researchers at the University of Colorado Anschutz Medical Campus indicate that the timing of midazolam administration during surgery may affect its link with heart injury. Medical professionals also emphasize that women should monitor for non-traditional heart attack signs such as unusual exhaustion, breathlessness, and indigestion rather than relying exclusively on chest pain.
Why it matters
These events follow recent pharmaceutical setbacks where drugs successfully met biological targets without preventing major medical events. Broader safety questions regarding pharmaceutical and surgical practices remain under scrutiny across the medical community. Research into inflammatory cell reduction using diabetes medications also shows potential for protecting the heart.
What is confirmed
- Novartis and Novo Nordisk experienced cardiovascular drug failures after failing to reduce major events despite hitting biological targets.
- Research from the University of Colorado Anschutz Medical Campus indicates that the timing of midazolam administration during surgery may affect its link with heart injury.
- Top cardiologists emphasize that women must monitor for non-traditional heart attack signs such as unusual exhaustion, breathlessness, and indigestion rather than relying solely on chest pain.
- Diabetes medications show potential in lowering inflammatory cell clumps to protect the heart.
What to watch next
- Further clinical data on diabetes medications reducing inflammatory cell clumps to protect the heart.
- Additional findings from the University of Colorado Anschutz Medical Campus regarding midazolam administration timing during surgery.
confidence 100%Sources used for this update (5)
- jen.jiji.com — Surprise in Shanghai, Alcaraz eliminated by Bergs in the third round
- jen.jiji.com — Innovation, Luppi (Assolombarda): "Key to increasing productivity"
- beforeitsnews.com — Byington Bombshell Report: Deep State's Planned Global Financial Crash Being Saved By Global Currency Res....
- timesofindia.indiatimes.com — Saudi Arabia Turns To Iran Amid Houthi Strikes, Dealing Trump A Major Gulf Blow? - Times of India Videos
- acilcivatavida.com — Another Blog Post - acilcivatavida.com
-
Hospital Drug Timing Linked to Heart Risk as Treatment Failures Mount
Recent research from the University of Colorado Anschutz Medical Campus indicates that the timing of midazolam administration during surgery may affect its link with heart injury. This development follows recent cardiovascular drug failures by Novartis and Novo Nordisk, which failed to reduce major events despite hitting biological targets. Meanwhile, top cardiologists emphasize that women must monitor for non-traditional heart attack signs such as unusual exhaustion, breathlessness, and indigestion rather than relying solely on chest pain. While diabetes medications show potential in lowering inflammatory cell clumps to protect the heart, broader pharmaceutical and surgical safety questions remain under scrutiny.
Why it matters
Heart disease treatment faces ongoing hurdles following recent failures from major pharmaceutical companies to protect patients from major cardiovascular events. Researchers continue to examine surgical variables, such as the administration timing of common hospital sedatives like midazolam, to understand potential links to heart injury. Concurrently, medical experts are working to educate the public on subtle and easily overlooked warning signs of blocked arteries, particularly in women who may not experience classic symptoms.
What is confirmed
- Doctors often give midazolam before surgery to help patients feel calm and sleepy, and to reduce their memory of the procedure.
- A team at the University of Colorado Anschutz Medical Campus examined more than 1.7 million surgery records to study midazolam timing and heart injury links.
- Dr Arpit K Patel highlighted five warning signs women should take seriously, noting that heart problems do not always announce themselves with dramatic chest pain.
Still unconfirmed
- The exact biological mechanism connecting the timing of midazolam administration to nighttime heart risk remains fully detailed or resolved.
What to watch next
- Further findings from the University of Colorado Anschutz Medical Campus regarding surgery records and midazolam timing.
- Additional clinical trials testing diabetes medications and other therapies for heart protection following recent drug failures.
confidence 85%Sources used for this update (4)
- knowridge.com — This Common Hospital Drug Linked to Nighttime Heart Risk
- www.respiratorytherapyzone.com — Cardiovascular Drugs: Overview and Practice Questions (2026)
- timesofindia.indiatimes.com — America's top cardiologist warns women not to ignore these 5 signs of blocked arteries, even without ches....
- www.marketbeat.com — IONS News Today | Why did Ionis Pharmaceuticals stock go up ...
-
Diabetes drug reduces inflammation in human trial
A human trial found that a popular diabetes medication significantly lowers inflammatory cell clumps, a result that may protect the heart. Participants showed a notable drop in these clumps within two weeks, with the effect strengthening by week 12. This finding provides a potential lead for heart protection following recent failures by Novartis and Novo Nordisk, whose cardiovascular drugs failed to reduce major events despite hitting biological targets.
Why it matters
Heart failure affects millions of older adults, causing fatigue and fluid retention. Researchers are struggling to use genetic biomarkers to predict which treatments will successfully lower cardiovascular events.
What is confirmed
- A popular diabetes drug lowered inflammatory cell clumps in a human trial.
- The reduction in inflammatory cell clumps was significant within two weeks and grew stronger by week 12.
What to watch next
- Clinical data confirming if the reduction in inflammation leads to a decrease in major cardiovascular events
- Further research on the specific diabetes drug's impact on heart failure patients
confidence 100%Sources used for this update (3)
- jen.jiji.com — Awards: Euro-Mediterranean, from Mihajlović to Fiona May, Stefano Mei and Daniele Santarelli protagonists of the IV edition (2)
- jen.jiji.com — Ericsson, Palazzo Chigi sources: Meloni calls CEO Missori, company withdraws 131 layoffs in Genoa
- news.vumc.org — Human trial: Popular diabetes drug shown to lower inflammation, which may protect the heart
-
Cardiovascular Drug Failures Stun Researchers
Recent clinical setbacks for cardiovascular medications leave cardiologists questioning the reliability of genetic biomarkers in drug development. Novartis and Novo Nordisk experienced trial failures where drugs hit biological targets but failed to lower major cardiovascular events. Researchers continue evaluating treatments for heart failure, a condition affecting millions of older adults that causes fatigue, weakness, and fluid retention by preventing the heart from moving sufficient blood throughout the body. These therapeutic failures complicate efforts to predict effective future heart treatments using DNA evidence.
Why it matters
Cardiologists face mounting challenges as drug trials miss primary endpoints despite successful target engagement. These setbacks disrupt traditional reliance on genetic biomarkers for predicting patient outcomes. The ongoing difficulties in heart failure treatment development underscore the complex nature of cardiovascular diseases in older populations.
What is confirmed
- Novartis and Novo Nordisk experienced trial failures where drugs successfully hit biological targets but failed to lower major cardiovascular events.
- Heart failure is a condition affecting millions of older adults that causes fatigue, weakness, and fluid retention by preventing the heart from moving sufficient blood throughout the body.
What to watch next
- Further clinical data on genetic biomarker reliability in cardiovascular drug development
- Updates from researchers evaluating new heart failure treatments
confidence 100%Sources used for this update (4)
- dictionary.cambridge.org — ANOTHER | English meaning - Cambridge Dictionary
- myanimelist.net — Another (TV 2012) - MyAnimeList.net
- en.wikipedia.org — Another (novel) - Wikipedia
- thespinoff.co.nz — Losing the clot: the story of how I nearly died, by Graeme Lay | The Spinoff
-
Another Heart Drug Fails, Shocking Cardiologists
Recent clinical setbacks for cardiovascular medications have left cardiologists questioning the reliability of genetic biomarkers in drug development. Novartis and Novo Nordisk both experienced trial failures where drugs successfully hit biological targets but failed to lower major cardiovascular events. Meanwhile, researchers continue evaluating treatments for heart failure, a condition affecting millions of older adults that causes fatigue, weakness, and fluid retention by preventing the heart from moving sufficient blood throughout the body. These mounting therapeutic failures complicate efforts to predict effective future heart treatments using DNA evidence.
Why it matters
Cardiovascular drug development relies heavily on genetic biomarkers to predict treatment efficacy before large-scale clinical trials. Recent high-profile failures by major pharmaceutical companies challenge this foundational assumption. As heart failure remains a leading cause of hospital admissions, understanding why biomarker-targeted therapies fail to reduce actual clinical events is critical for future research.
Still unconfirmed
- Novartis phase 3 Lp(a)HORIZON trial for pelacarsen failed to produce a statistically significant reduction in major cardiovascular events despite lowering lipoprotein(a) targets.
- Novo Nordisk ziltivekimab hit biomarker targets in major heart disease trials but failed to reduce cardiovascular events.
What to watch next
- Further clinical trial results for cardiovascular medications targeting genetic biomarkers
- Regulatory updates regarding drug development standards for heart disease
confidence 50%Sources used for this update (5)
- jen.jiji.com — Flydubai, the hero pilot's story to Modi: "I couldn't let the passengers die" - Video
- jen.jiji.com — Rare diseases, Tonolo (Anmar): "IgG4-related disease is completely unknown"
- knowridge.com — Common Heart Drug May Worsen Some Heart Failure
- nashvillebanner.com — Christa Pike survives botched lethal injection attempt ...
- abcnews.com — The drug used in Tennessee's failed execution has come under past scrutiny
-
Cardiologists Face More Trial Failures As Heart Drugs Miss Goals
Cardiologists face mounting setbacks as multiple cardiovascular drugs fail in clinical trials and regulatory reviews, challenging the reliability of genetic biomarkers in drug development. Novartis saw its phase 3 Lp(a)HORIZON trial for pelacarsen fail to produce a statistically significant reduction in major cardiovascular events, despite successfully lowering lipoprotein(a) targets. Similarly, Novo Nordisk's ziltivekimab hit biomarker targets in major heart disease trials but failed to reduce cardiovascular events. These trial failures raise difficult questions regarding what DNA evidence can predict for future heart treatments.
Why it matters
Genetic and biomarker approaches formed the basis of several high-profile cardiovascular drug development programs. The recent failures of pelacarsen and ziltivekimab demonstrate that successfully modifying specific biological targets does not automatically translate to preventing major adverse heart events. These outcomes force researchers to reevaluate standard paradigms in cardiovascular pharmacology and clinical trial design.
What is confirmed
- Novartis AG's phase 3 Lp(a)HORIZON setback means pelacarsen significantly lowered lipoprotein(a) but failed to produce a statistically significant reduction in major cardiovascular events.
- Novartis's pelacarsen and Novo Nordisk's ziltivekimab both hit their biomarker targets in massive heart disease trials without reducing cardiovascular events.
- The FDA rejected Cytokinetics cardiac myosin activator omecamtiv mecarbil as a treatment for heart failure based on lacking efficacy data.
- Tenax shares lost over 85% of their value after its drug for pulmonary hypertension caused by a form of heart failure flunked a phase 3 trial.
What to watch next
- Further clinical data releases from drug developers attempting to validate genetic biomarkers for cardiovascular protection.
- Additional regulatory decisions from the FDA regarding cardiovascular and heart failure therapeutics.
confidence 100%Sources used for this update (16)
- www.sciencedaily.com — ScienceDaily: Your source for the latest research news
- sports.yahoo.com — MLB Latest Updates - Yahoo Sports
- www.eurasiareview.com — The Treatment Was Worse Than The Disease – OpEd
- jen.jiji.com — Ranucci and Report case, the president of the Rome Court: "Support for judge Casari, assignment respects the rules"
- jen.jiji.com — UK, 5 arrested for incident near Raf base released on bail
- www.news-medical.net — Semaglutide cuts major heart events, but researchers still cannot fully explain why
- pharmaphorum.com — FDA rejects Cytokinetics’ heart failure drug - pharmaphorum
- pharmaphorum.com — Tenax trounced by phase 3 heart failure readout | pharmaphorum
- biologyinsights.com — Dapagliflozin: A Breakthrough Treatment for HFpEF - Biology ...
- finance.yahoo.com — Failure of Novartis’ Pelacarsen Could Reshape the Lp(a) Race ...
- www.medscape.com — Heart Failure News - Index - Medscape
- biotechmorning.com — Genetics Said These Heart Drugs Should Work. The Patients ...
-
Diabetes Study Links Type 2 Diagnosis to Heart and Kidney Failure
A study of 1.6 million patients indicates that up to one third of people with type 2 diabetes develop kidney disease, heart failure, or die within five years of their diagnosis. This finding arrives as the cardiology sector manages losses from drug trial failures. While oncology saw a win with the FDA approval of WELIREG and LENVIMA for advanced renal cell carcinoma on September 25, 2026, the cardiovascular field faces ongoing challenges in treating chronic comorbidities associated with metabolic disorders.
Why it matters
Heart and kidney complications are common secondary effects of long-term diabetes. Reducing these risks is a primary goal for cardiologists and endocrinologists. Recent pharmaceutical pipeline failures have limited new treatment options for these patients.
Still unconfirmed
- Up to a third of people with type 2 diabetes will develop heart failure, kidney disease or die within five years of diagnosis.
What to watch next
- Clinical trial results for new heart failure medications
- Updated FDA guidelines for diabetes-related cardiac care
confidence 60%Sources used for this update (2)
- www.dailymail.com — Up to one in three people with type 2 diabetes develop serious heart or kidney disease or die within five years of diagnosis, study of 1.6 million patients suggests
- www.omanobserver.om — He changed the world of organ transplants. Would he die waiting for his own?
-
FDA Approves WELIREG Plus LENVIMA for Advanced Renal Cell Carcinoma
Federal regulators approved the combination of WELIREG and LENVIMA to treat specific adult patients with advanced renal cell carcinoma featuring a clear cell component. The approval by the U.S. Food and Drug Administration on September 25, 2026, provides a new therapeutic option for previously treated individuals facing this challenging cancer diagnosis. Pharmaceutical companies Merck and Eisai announced the regulatory decision from Rahway, New Jersey, and Nutley, New Jersey, expanding treatment pathways in oncology while the separate cardiology sector continues to absorb pipeline losses from recent drug trial failures.
Why it matters
The regulatory green light arrives as the broader pharmaceutical sector navigates mixed fortunes across different therapeutic areas. While oncology treatments advance with new combination approvals, cardiovascular medicine recently absorbed severe mid-stage trial failures that left physicians without approved options for specific genetic risk factors affecting twenty percent of the population. Understanding these contrasting regulatory outcomes helps clarify how pharmaceutical developers allocate resources between oncology advancements and troubled cardiovascular pipelines.
What is confirmed
- The U.S. Food and Drug Administration approved WELIREG plus LENVIMA for certain previously treated adult patients with advanced renal cell carcinoma with a clear cell component on September 25, 2026.
What to watch next
- Commercial availability and pricing announcements for the approved drug combination
- Additional clinical data regarding patient outcomes for the WELIREG and LENVIMA regimen
confidence 100%Sources used for this update (2)
- jen.jiji.com — UniMarconi, on September 26 'A Lesson in the Square' returns, a discussion in Italian cities
- finance.yahoo.com — U.S. FDA Approves WELIREG® (belzutifan) Plus LENVIMA® (lenvatinib) for Certain Previously Treated Adult Patients With Advanced Renal Cell Carcinoma With a Clear Cell ...
-
ICD Study Confirms Life-Saving Impact for HCM Patients
Implanted cardioverter-defibrillators have saved nearly one in six hypertrophic cardiomyopathy patients, according to a new Circulation study. This confirms the life-saving value of the devices and supports their continued use in cardiology practice. Meanwhile, the cardiovascular field faces severe pipeline losses after recent mid-stage trial failures from Longeveron, Novo Nordisk, and Novartis. These setbacks leave physicians without approved treatments for specific genetic risk factors affecting twenty percent of the population. Longeveron retains just over ten million dollars in cash to fund operations through the end of the year.
Why it matters
The recent failure of Longeveron's stem cell therapy study compounds a difficult period for cardiovascular drug development. Previous setbacks from Novo Nordisk and Novartis left significant treatment gaps for high-risk patients. Device therapies like implantable cardioverter-defibrillators remain critical tools while pharmacological options struggle to secure approval.
What is confirmed
- A new Circulation study confirmed that implanted cardioverter-defibrillators have saved nearly one in six hypertrophic cardiomyopathy patients.
What to watch next
- Further clinical data on hypertrophic cardiomyopathy treatments
- Updates on Longeveron operational funding beyond 2026
confidence 100%Sources used for this update (3)
- www.ibtimes.co.uk — Donald Trump Appears To Drift off With 'Eyes Getting Heavy' and 'Face Dropping' at Oval Office Briefing
- jen.jiji.com — Serie A, today Milan-Lecce - Live
- cardiacwire.com — ICDs in HCM Patients, A Life Saving Combo
-
Longeveron Stem Cell Therapy Failure Leaves Genetic Heart Risks Untreated
Longeveron is reviewing its strategy after a mid-stage cardiovascular study for its stem cell therapy failed. The company has just over $10 million in cash to fund operations through the end of 2026. This failure follows recent setbacks from Novo Nordisk's IL-6 program and Novartis's pelacarsen in the Lp(a)HORIZON trial. Together, these failures leave physicians without approved treatments for specific genetic risk factors that impact 20 percent of the population.
Why it matters
The industry is struggling to address high-risk genetic markers for heart disease. Repeated failures across different drug classes indicate a significant gap in available therapies for a large portion of the population.
Still unconfirmed
- A 77-year-old woman named Susan experienced a deadly heart condition triggered by weight-loss injections.
What to watch next
- The outcome of Longeveron's strategic review
- Further trial results for genetic cardiovascular treatments
confidence 80%Sources used for this update (2)
- jen.jiji.com — Milan, Tales project tells science to the city in 30 photos
- www.dailymail.com — I was constantly exhausted but put it down to my age. It was a deadly heart condition triggered by weight-loss jabs - and thousands more could be at risk
-
Longeveron Stem Cell Therapy Fails Mid-Stage Cardiovascular Trial
Longeveron is conducting a strategic review after its stem cell therapy failed a mid-stage cardiovascular study. The company holds just over $10 million in cash to fund operations through the end of 2026. This failure adds to a string of recent setbacks in heart disease treatment, following the failure of Novartis's pelacarsen in the Lp(a)HORIZON trial and a 2026 failure in Novo Nordisk's IL-6 program. These results leave physicians without approved treatments for specific genetic risk factors affecting 20 percent of the population.
Why it matters
Cardiologists are struggling to find effective treatments for inherited and genetically determined heart risks. While some experimental drugs show potential for improving exercise capacity in inherited heart disease, several high-profile trials have missed their primary outcomes.
What is confirmed
- Longeveron is performing a strategic review after a cardiovascular study failure.
- Longeveron has just over $10 million in cash to fuel operations through the end of the year.
- Novartis's pelacarsen failed to reduce cardiovascular events in the Lp(a)HORIZON trial.
- Novo Nordisk's IL-6 program suffered a trial failure in 2026.
- Lipoprotein(a) risk factors affect roughly twenty percent of the general population.
Still unconfirmed
- An experimental drug has shown potential to improve heart failure status and symptoms in patients with inherited heart disease.
What to watch next
- The outcome of Longeveron's strategic review
- Further data on experimental drugs for inherited heart disease
confidence 90%Sources used for this update (4)
- medicalxpress.com — Experimental drug shows potential for hard-to-treat heart disease
- jen.jiji.com — Pietracatella Mystery, ricin traces emerged from expert reports confirming murder hypothesis
- www.yahoo.com — 10 Vintage Health Products That Could Have Easily Killed You
- www.biospace.com — Longeveron’s shares crash as stem cell therapy flunks mid-stage cardio trial
-
Cardiologists Face Treatment Gap After Pelacarsen Trial Fails
Novartis announced that pelacarsen failed to reduce cardiovascular events in patients with established disease and elevated lipoprotein(a). Although the drug successfully lowered the protein particle, it missed its primary outcome in the Lp(a)HORIZON trial. This setback follows a separate trial failure in 2026 from Novo Nordisk's IL-6 program. Cardiologists expected the drug to be an effective tool against heart attacks, but the negative results leave physicians without an approved treatment for the genetically determined lipoprotein(a) risk factor. This specific risk factor affects roughly twenty percent of the general population.
Why it matters
The failure of pelacarsen deals a heavy blow to cardiology specialists who lack targeted options to lower lipoprotein(a), an inherited risk factor for cardiovascular disease. This trial miss also damaged broader sector sentiment, contributing to a 6.2 percent weekly slide for BioNTech as investor confidence wavered across the biotech industry.
What is confirmed
- Novartis announced that pelacarsen failed to reduce cardiovascular events in patients with established disease and elevated lipoprotein(a).
- The drug successfully lowered the protein particle but missed its primary outcome in the Lp(a)HORIZON trial.
- The genetically determined lipoprotein(a) risk factor affects roughly 20% of the population.
- BioNTech slid 6.2% for the week as the pelacarsen miss hit biotech sentiment.
What to watch next
- Further disclosures from Novartis regarding the Lp(a)HORIZON trial data
- Future developments in alternative pipeline treatments addressing lipoprotein(a)
confidence 100%Sources used for this update (7)
- jen.jiji.com — US Open, today Shelton-Tiafoe: time, head-to-head, and where to watch it on TV
- jen.jiji.com — US Open, today Zverev-Khachanov: schedule, head-to-head and where to watch it on TV
- inews.co.uk — I’m a doctor – menopause supplements are the biggest rip-off of them all
- jen.jiji.com — Misano GP, Bezzecchi show and record pole position: the starting grid of the San Marino Grand Prix
- jen.jiji.com — Lady Gaga becomes a mother, first child born with Michael Polansky
- jen.jiji.com — Large fire in Positano causes landslide on 'Amalfitana' road, firefighters at work
- www.ad-hoc-news.de — BioNTech's Rough Week: A Sector Shock, a Founder's Sell-Down, and a Pipeline That Says Otherwise
-
Novartis Heart Drug Pelacarsen Fails Primary Outcome in Lp(a)HORIZON Trial
Novartis announced that pelacarsen failed to reduce cardiovascular events in patients with established disease and elevated lipoprotein(a). While the drug successfully lowered the protein particle, it did not meet its primary outcome in the Lp(a)HORIZON trial. This failure comes alongside a separate 2026 trial flop from Novo Nordisk's IL-6 program. Cardiologists had expected the drug to be a major tool against heart attacks, but the results leave physicians without an approved treatment for the genetically determined lipoprotein(a) risk factor, which affects roughly 20% of the population.
Why it matters
Lipoprotein(a) is a protein linked to higher heart risk that is primarily determined by genetics. Pelacarsen was the first cardiovascular outcomes trial designed specifically to target this particle. The failure marks a setback for a pharmaceutical strategy focused on genetic heart disease risk.
What is confirmed
- Novartis announced that pelacarsen failed to achieve its primary outcome in the Lp(a)HORIZON trial.
- The drug successfully lowered lipoprotein(a) but did not reduce cardiovascular events in patients with established disease and elevated Lp(a).
- Lipoprotein(a) is linked to higher heart risk in approximately one in five people.
- There are currently no approved therapies to lower lipoprotein(a).
- Pharma companies invested billions of dollars to develop these heart disease treatments.
Still unconfirmed
- Ethan Weiss suggests the failures of the Novartis and Novo Nordisk programs end the era where genetics is considered undefeated in heart drugs.
What to watch next
- Development of alternative therapies for lipoprotein(a) reduction.
confidence 100%Sources used for this update (6)
- medicalxpress.com — Cardiologists expected this new drug to prevent heart attacks—so why did it fail?
- jen.jiji.com — Alzheimer, hope from the placenta: "Nasal spray defends neurons and memory"
- www.afr.com — Blanche d’Alpuget dies; Bathla projects taken over by Bob Ell; LIV Golf’s bankruptcy a warning sign for markets
- jen.jiji.com — Fuel prices, Council of Ministers approves 7-day extension of excise duty cut
- finance.biggo.com — Ethan Weiss: Two Trial Flops End the "Genetics Is Undefeated" Era in Heart Drugs
- www.statnews.com — Why two promising heart drugs flopped and what’s next
-
Pelacarsen Trial Failure Leaves Heart Drugs Without Lp(a) Success
Novartis announced that pelacarsen failed to achieve its primary outcome in the Lp(a)HORIZON trial. Although the agent successfully lowered lipoprotein(a), it did not reduce cardiovascular events in patients with established disease and elevated Lp(a). This marks the first cardiovascular outcomes trial for a therapy designed to target lipoprotein(a), a protein particle linked to higher heart risk in approximately one in five people. Currently, there are no approved therapies to lower lipoprotein(a), which is primarily determined by genetics, leaving cardiologists without a proven treatment pathway for this specific risk factor.
Why it matters
Elevated lipoprotein(a) is a genetically determined protein particle associated with a higher risk of heart disease in a significant portion of the population. The Lp(a)HORIZON trial represented a major effort to address this specific cardiovascular risk factor through targeted pharmacological intervention. Because the trial failed to reduce actual cardiovascular events despite successfully lowering the protein levels, researchers face a critical setback in developing effective treatments for this condition.
What is confirmed
- Novartis announced that pelacarsen failed to achieve its primary outcome in the Lp(a)HORIZON trial.
- Pelacarsen successfully lowered lipoprotein(a) but did not reduce cardiovascular events in patients with established disease and elevated Lp(a).
- The Lp(a)HORIZON trial is the first cardiovascular outcomes trial for an agent designed to lower lipoprotein(a).
- Lipoprotein(a) is a protein particle associated with higher heart risk in roughly one in five people and is primarily determined by genetics.
- There are currently no approved therapies to lower lipoprotein(a).
What to watch next
- Further clinical data releases from Novartis regarding the Lp(a)HORIZON trial
- Regulatory or industry responses to the lack of approved therapies for lowering lipoprotein(a)
confidence 100%Sources used for this update (4)
- jen.jiji.com — Ranucci, Cangiano: "Journalist under investigation after my complaint"
- jen.jiji.com — Champions League, all today's matches and where to watch them
- www.dailymail.com — Chewing gum sales are up, phone scrolling is down and everyone is hiding food in napkins at parties...how three years of Mounjaro have changed our daily habits in w…
- www.capitalbrief.com — Oil close to USD100 amid US strikes near Kharg Island
-
Pelacarsen Fails to Reduce Cardiovascular Events in Phase III Trial
Novartis announced that pelacarsen failed to achieve its primary outcome in the Lp(a)HORIZON trial. While the drug successfully lowered lipoprotein(a), it did not reduce cardiovascular events in patients with established disease and elevated Lp(a). This represents the first cardiovascular outcomes trial for an agent designed to lower Lp(a), a protein particle associated with higher heart risk in roughly one in five people. There are currently no approved therapies to lower Lp(a), which is primarily determined by genetics.
Why it matters
Cardiologists viewed this drug as a potential breakthrough for a genetic risk factor that remains untreatable. The failure raises questions about whether lowering Lp(a) alone is sufficient to improve patient outcomes. This occurs amid a broader trend where over two-thirds of 2024 FDA-approved drugs relied on a single study.
What is confirmed
- The Lp(a)HORIZON trial of pelacarsen failed to achieve its primary outcome.
- Pelacarsen successfully lowered levels of the Lp(a) protein particle.
- High levels of Lp(a) occur in about one in five people and are associated with elevated risk for CV events.
- No therapies are currently approved to lower Lp(a).
What to watch next
- Analysis of secondary endpoints from the Lp(a)HORIZON trial
- Novartis statements on the future development of pelacarsen
confidence 100%Sources used for this update (7)
- economictimes.indiatimes.com — Persistent systems Q4 results
- www.yahoo.com — I Thought Cheating Was Unforgivable. Then A Friend's Affair Made Me Question Everything.
- au.lifestyle.yahoo.com — 5 Ways To Keep The Weight Off After Weaning Off A GLP-1 Drug
- jen.jiji.com — Iran, army: US drone shot down over Hormuz
- jen.jiji.com — Sfera Ebbasta case at San Siro, Lucarelli brings up the comparison with Elodie and the dance troupe: what's happening
- www.statnews.com — Pharmalittle: We’re reading about another Novartis trial failure, a Novo Nordisk setback, and more
- www.healio.com — ‘Not the results we hoped for’: Lp(a)-lowering drug pelacarsen fails to reduce CV events
-
Novartis Drug Failure Questions New Heart Medicines
An experimental cardiovascular drug developed by Novartis and Ionis called pelacarsen failed its Phase III Lp(a)HORIZON trial. The late-stage study targeted patients with established cardiovascular disease and elevated Lp(a). Although the treatment successfully lowered levels of the Lp(a) protein particle, it failed to protect heart health or meet its primary endpoint. This unexpected outcome has surprised cardiologists and raised broader questions about the future of this emerging class of heart medications.
Why it matters
The unsuccessful trial represents a major setback for researchers pursuing novel approaches to lower cardiovascular risk through targeted protein reduction. Pelacarsen was evaluated in a large clinical trial designed to treat patients suffering from elevated Lp(a) and established heart disease. The topline results confirmed the drug missed its necessary goals, challenging existing assumptions about how lowering this specific particle impacts patient survival and health.
What is confirmed
- Novartis announced that its experimental cardiovascular drug pelacarsen failed to meet its primary endpoint in the Lp(a)HORIZON Phase III trial.
- The study targeted patients with established cardiovascular disease and elevated Lp(a).
- Pelacarsen was developed in partnership with Ionis.
- Pelacarsen successfully lowered levels of a protein particle known as Lp(a) in a large clinical trial.
- The drug did not protect heart health despite lowering Lp(a) levels, surprising cardiologists and raising questions about an emerging class of heart medicines.
What to watch next
- Further data releases or analyses from the Lp(a)HORIZON Phase III trial by Novartis and Ionis
- Decisions by researchers and developers regarding the future path of emerging Lp(a)-lowering cardiovascular therapies
confidence 100%Sources used for this update (4)
- www.dailymail.com — How to ditch your blood pressure pills: Fed up with side effects or worried about the dangers? These are the simple changes that could help you get off the medication f…
- finance.yahoo.com — Novartis, Ionis drug failure spurs questions about an emerging class of heart medicines
- jen.jiji.com — Workplace harassment, even unwanted caresses and confidences can be compensated
- medicalxpress.com — Immediate coronary angiography fails to boost survival after cardiac arrest, trial finds
-
Novartis Pelacarsen Fails Phase III Heart Disease Trial
Novartis announced that its experimental cardiovascular drug pelacarsen failed to meet its primary endpoint in the Lp(a)HORIZON Phase III trial. The study targeted patients with established cardiovascular disease and elevated Lp(a). The failure of this late-stage trial has surprised cardiologists and represents a setback for a new approach to treating heart disease. The drug was developed in partnership with Ionis. Novartis released the topline results confirming the drug did not achieve the necessary goals for the pivotal study.
Why it matters
Pelacarsen was designed to lower Lp(a), a specific type of lipoprotein linked to heart disease. This trial aimed to prove that reducing these levels could prevent cardiovascular events. The failure challenges the current experimental strategy for this specific heart disease pathway.
What is confirmed
- Novartis announced that pelacarsen missed its primary endpoint in the Lp(a)HORIZON Phase III trial.
- The trial included patients with established cardiovascular disease and elevated Lp(a).
- Ionis is a key partner in the development of the experimental heart drug.
What to watch next
- Detailed data release from the Lp(a)HORIZON trial
- Novartis and Ionis official statement on the future of the pelacarsen program
confidence 100%Sources used for this update (11)
- The New York Times — Another Heart Drug Fails, Shocking Cardiologists
- Novartis — Novartis announces Lp(a)HORIZON Phase III topline results for pelacarsen in patients with elevated Lp(a) and established cardiovascular disease (CVD)
- reuters.com — Ionis, Novartis' key experimental heart drug fails in late-stage trial
- STAT — Novartis’ experimental cardiovascular drug fails a pivotal study
- Bloomberg.com — Novartis Drug Fails Key Test for New Heart Disease Approach
- WSJ — Novartis Says Pelacarsen Heart Disease Drug Missed Primary Endpoint
- GlobeNewswire — Novartis announces Lp(a)HORIZON Phase III topline results
- www.dailymail.com — Exposing the great wellness racket: From wonder supplements to tell-all health trackers, doctor and broadcaster XAND VAN TULLEKEN unmasks the troubling trut…
- jen.jiji.com — Meloni: "The South is growing faster than the national average, now a priority for the too many young people leaving"
- www.dailymail.com — Married influencer killed by penis enlargement surgery during dream vacation: He passed out while receiving a massage with his wife... then never woke up
- jen.jiji.com — US Open, today Cobolli-Blockx - Live
Community Sentiment: How do you assess this situation?
Voice your perspective · Real-time aggregated sentiment from the Live Feeds community